PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Korean Journal of Internal Medicine10.3904/kjim.2016.2052019343579-587Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patientsDa Hea Seo, Yongin Cho, Sujin Lee, Seho Park, Seung-Il Kim, Byeong Woo Park, Yumie Rheehttp://kjim.org/upload/kjim-2016-205.pdf, http://kjim.org/journal/view.php?doi=10.3904/kjim.2016.205, http://www.kjim.org/upload/kjim-2016-205.pdf
The Breast10.1016/s0960-9776(07)70050-4200716S8S27 Application of aromatase inhibitors in endocrine responsive breast cancersP.E. Gosshttps://api.elsevier.com/content/article/PII:S0960977607700504?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977607700504?httpAccept=text/plain
The Breast10.1016/j.breast.2007.07.011200716114-119Application of aromatase inhibitors in endocrine responsive breast cancersPaul Goss, Melinda Wuhttps://api.elsevier.com/content/article/PII:S0960977607001439?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977607001439?httpAccept=text/plain
The Breast10.1016/j.breast.2019.01.010201945119Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancerKai Zhang, Qilin Tanghttps://api.elsevier.com/content/article/PII:S0960977619300104?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977619300104?httpAccept=text/plain
Clinical Breast Cancer10.3816/cbc.2009.n.037200994219-224Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast CancerKaren W. Kwan, Rowan T. Chlebowskihttps://api.elsevier.com/content/article/PII:S1526820911706711?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911706711?httpAccept=text/plain
Breast Cancer Research10.1186/bcr2543201012S1Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancerS Weeraman, C Hunsley, M Wall, R Kirbyhttp://link.springer.com/content/pdf/10.1186/bcr2543.pdf, http://link.springer.com/article/10.1186/bcr2543/fulltext.html, http://link.springer.com/content/pdf/10.1186/bcr2543.pdf
European Journal of Cancer Supplements10.1016/s1359-6349(06)80377-0200642152Amenorrhea as a prognostic factor in premenopausal endocrine responsive early breast cancer patientsT. Globokar, Snoj, A. Sadikov, T. Cuferhttps://api.elsevier.com/content/article/PII:S1359634906803770?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634906803770?httpAccept=text/plain
Breast Cancer Research10.1186/bcr154620068S2Evolution of aromatase inhibitors as an endocrine treatment for breast cancerWR Millerhttp://link.springer.com/content/pdf/10.1186/bcr1546.pdf, http://link.springer.com/article/10.1186/bcr1546/fulltext.html, http://link.springer.com/content/pdf/10.1186/bcr1546.pdf
Clinical Breast Cancer10.3816/cbc.2004.s.00920045S13-S17Switching Trial of Adjuvant Tamoxifen with an Aromatase Inhibitor in Postmenopausal Patients with Breast CancerFrancesco Boccardohttps://api.elsevier.com/content/article/PII:S1526820911704050?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911704050?httpAccept=text/plain
Breast Cancer Research and Treatment10.1007/s10549-018-05086-820191743785-794Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivorsXiaoqing Xu, Rowan T. Chlebowski, Jiaxiao Shi, Ana Barac, Reina Haquehttp://link.springer.com/article/10.1007/s10549-018-05086-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-018-05086-8.pdf, http://link.springer.com/content/pdf/10.1007/s10549-018-05086-8.pdf